Welkom bij Scalda & Bohn Stafleu van Loghum
Scalda heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen.Je kunt de producten hieronder links aanschaffen en rechts inloggen.
Gepubliceerd in:
2025 | OriginalPaper | Hoofdstuk
21. Maligne tumoren van de weke delen
Auteurs : W. T. A. van der Graaf, J. V. M. G. Bovée, R. L. M. Haas, D. J. Grünhagen
Gepubliceerd in: Leerboek oncologie – online voorpublicatie
Uitgeverij: BSL Media & Learning
share
DELEN
Deel dit onderdeel of sectie (kopieer de link)
-
Optie A:
-
Optie B:Deel de link per e-mail
Samenvatting
Maligne tumoren van de wekedelen (sarcomen) vormen samen een scala van heel verschillende tumoren van mesenchymale herkomst. Het is essentieel de diagnose op een juiste wijze te stellen, waarbij zo veel mogelijk informatie uit het biopt verkregen moet worden, met een belangrijke rol voor immuunhistochemie en moleculaire diagnostiek. De standaardbehandeling bestaat uit chirurgie, vaak aangevuld met radiotherapie. Indien ledemaatsparende chirurgie niet primair mogelijk is, is geïsoleerde ledemaatperfusie met melfalan en TNF-α te overwegen. Chemotherapie is geen standaardonderdeel van de primaire behandeling, tenzij er sprake is van een rabdomyosarcoom op kinder- en jongvolwassen leeftijd of van een (extraossaal) Ewing-sarcoom of extraskeletaal osteosarcoom. Bij het gemetastaseerde wekedelensarcoom is er plaats voor palliatieve chemotherapie, met als meest effectieve cytostatica doxorubicine en ifosfamide. Nieuwe kennis van tumorbiologie in wekedelensarcomen heeft geleid tot meer inzicht in de verscheidenheid aan diagnoses en mogelijke behandelingsmogelijkheden. Daarnaast zijn de gevonden mutaties in gastro-intestinale stromale tumoren (GIST) een goed doelwit van diverse doelgerichte behandelingen
Log in om toegang te krijgen
Literatuur
go back to reference Bastiaannet E, Groen H, Jager PL, et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev. 2004;30:83–101.CrossRefPubMed
Bastiaannet E, Groen H, Jager PL, et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev. 2004;30:83–101.CrossRefPubMed
go back to reference Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;7:923–34.CrossRef
Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;7:923–34.CrossRef
go back to reference Blay JY, Soibinet P, Penel N, Bompas E, Duffaud F, Stoeckle E, et al. NETSARC/RREPS and French Sarcoma Group-Groupe d’Etude des Tumeurs Osseuses (GSF-GETO) networks. Ann Oncol. 2017;28(11):2852–9.CrossRefPubMedPubMedCentral
Blay JY, Soibinet P, Penel N, Bompas E, Duffaud F, Stoeckle E, et al. NETSARC/RREPS and French Sarcoma Group-Groupe d’Etude des Tumeurs Osseuses (GSF-GETO) networks. Ann Oncol. 2017;28(11):2852–9.CrossRefPubMedPubMedCentral
go back to reference Bonvalot S, Gronchi A, Le Péchoux C, Swallow CJ, Strauss D, Meeus P, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21:1366–77.CrossRefPubMed
Bonvalot S, Gronchi A, Le Péchoux C, Swallow CJ, Strauss D, Meeus P, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21:1366–77.CrossRefPubMed
go back to reference Casali PG, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(1):20–33.CrossRefPubMed
Casali PG, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(1):20–33.CrossRefPubMed
go back to reference Davis AM, O’Sullivan B, Bell RS, Turcotte R, Catton CN, Wunder JS, et al. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol. 2002;20:4472–7.CrossRefPubMed
Davis AM, O’Sullivan B, Bell RS, Turcotte R, Catton CN, Wunder JS, et al. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol. 2002;20:4472–7.CrossRefPubMed
go back to reference De Jong MA, Oldenborg S, Bing Oei S, Griesdoorn V, Kolff MW, Koning CC, Van Tienhoven G. Reirradiation and hyperthermia for radiation-associated sarcoma. Cancer. 2012;118:180–7.CrossRefPubMed
De Jong MA, Oldenborg S, Bing Oei S, Griesdoorn V, Kolff MW, Koning CC, Van Tienhoven G. Reirradiation and hyperthermia for radiation-associated sarcoma. Cancer. 2012;118:180–7.CrossRefPubMed
go back to reference Desmoid Tumor Working Group. The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer. 2020;127:96–107.CrossRef
Desmoid Tumor Working Group. The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer. 2020;127:96–107.CrossRef
go back to reference Gounder M, Ratan R, Alcindor T, Schöffski P, Van der Graaf WT, Wilky BA, et al. Nirogacestat, a γ-Secretase inhibitor for desmoid tumors. N Engl J Med. 2023;388:898–912.CrossRefPubMedPubMedCentral
Gounder M, Ratan R, Alcindor T, Schöffski P, Van der Graaf WT, Wilky BA, et al. Nirogacestat, a γ-Secretase inhibitor for desmoid tumors. N Engl J Med. 2023;388:898–912.CrossRefPubMedPubMedCentral
go back to reference Graaf WT Van der, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al.; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879–86.
Graaf WT Van der, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al.; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879–86.
go back to reference Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer A, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:1348–65.CrossRefPubMed
Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer A, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:1348–65.CrossRefPubMed
go back to reference Gronchi A, Strauss DC, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, et al. Variability in patterns of recurrence after resection of Primary Retroperitoneal Sarcoma (RPS): a report on 1,007 patients from the multi-institutional collaborative Transatlantic RPS Working Group. Ann Surg. 2016;263:1002–9.CrossRefPubMed
Gronchi A, Strauss DC, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, et al. Variability in patterns of recurrence after resection of Primary Retroperitoneal Sarcoma (RPS): a report on 1,007 patients from the multi-institutional collaborative Transatlantic RPS Working Group. Ann Surg. 2016;263:1002–9.CrossRefPubMed
go back to reference Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997;15(1):350–62.CrossRefPubMed
Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997;15(1):350–62.CrossRefPubMed
go back to reference Haas RL, Baldini EH, Chung PW, Van Coevorden F, DeLaney TF. Radiation therapy in retroperitoneal sarcoma management. J Surg Oncol. 2018;117:93–8.CrossRefPubMed
Haas RL, Baldini EH, Chung PW, Van Coevorden F, DeLaney TF. Radiation therapy in retroperitoneal sarcoma management. J Surg Oncol. 2018;117:93–8.CrossRefPubMed
go back to reference Haas RL, Delaney TF, OʼSullivan B, Keus RB, Le Pechoux C, Olmi P, et al. Radiotherapy for management of extremity soft tissue sarcomas: why, when, and where? Int J Radiat Oncol Biol Phys. 2012;84:572–80.
Haas RL, Delaney TF, OʼSullivan B, Keus RB, Le Pechoux C, Olmi P, et al. Radiotherapy for management of extremity soft tissue sarcomas: why, when, and where? Int J Radiat Oncol Biol Phys. 2012;84:572–80.
go back to reference Husson O, Younger E, Dunlop A, Dean L, Strauss DC, Benson C, et al. Desmoid fibromatosis through the patients’ eyes: time to change the focus and organisation of care? Support Care Cancer. 2019;27:965–80.CrossRefPubMed
Husson O, Younger E, Dunlop A, Dean L, Strauss DC, Benson C, et al. Desmoid fibromatosis through the patients’ eyes: time to change the focus and organisation of care? Support Care Cancer. 2019;27:965–80.CrossRefPubMed
go back to reference Jones RL, Serrano C, Von Mehren M, George S, Heinrich MC, Kang YK, et al. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer. 2021;145:132–42.CrossRefPubMedPubMedCentral
Jones RL, Serrano C, Von Mehren M, George S, Heinrich MC, Kang YK, et al. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer. 2021;145:132–42.CrossRefPubMedPubMedCentral
go back to reference Jong MA de, Oldenborg S, Bing Oei S, Griesdoorn V, Kolff MW, Koning CC, Tienhoven G van. Reirradiation and hyperthermia for radiation-associated sarcoma. Cancer. 2012;118:180–7.
Jong MA de, Oldenborg S, Bing Oei S, Griesdoorn V, Kolff MW, Koning CC, Tienhoven G van. Reirradiation and hyperthermia for radiation-associated sarcoma. Cancer. 2012;118:180–7.
go back to reference Kurtz JE, Buy X, Deschamps F, Sauleau E, Bouhamama A, Toulmonde M, et al. CRYODESMO-O1: a prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment. Eur J Cancer. 2021;143:78–87.CrossRefPubMed
Kurtz JE, Buy X, Deschamps F, Sauleau E, Bouhamama A, Toulmonde M, et al. CRYODESMO-O1: a prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment. Eur J Cancer. 2021;143:78–87.CrossRefPubMed
go back to reference Lansu J, Bovée JVMG, Braam P, Van Boven H, Flucke U, Bonenkamp JJ, et al. Dose reduction of preoperative radiotherapy in myxoid liposarcoma: a nonrandomized controlled trial. JAMA Oncol. 2021;7: e205865.CrossRefPubMed
Lansu J, Bovée JVMG, Braam P, Van Boven H, Flucke U, Bonenkamp JJ, et al. Dose reduction of preoperative radiotherapy in myxoid liposarcoma: a nonrandomized controlled trial. JAMA Oncol. 2021;7: e205865.CrossRefPubMed
go back to reference Le Cesne A, Ouali M, Leahy MG, Santoro A, Hoekstra HJ, Hohenberger P, et al. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Ann Oncol. 2014;25:2425–32.CrossRefPubMed
Le Cesne A, Ouali M, Leahy MG, Santoro A, Hoekstra HJ, Hohenberger P, et al. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Ann Oncol. 2014;25:2425–32.CrossRefPubMed
go back to reference Nathenson MJ, Hu J, Ratan R, Somaiah N, Hsu R, DeMaria PJ, et al. Systemic chemotherapies retain antitumor activity in desmoid tumors independent of specific mutations in CTNNB1 or APC: a multi-institutional retrospective study. Clin Cancer Res. 2022;28(18):4092–104.CrossRefPubMedPubMedCentral
Nathenson MJ, Hu J, Ratan R, Somaiah N, Hsu R, DeMaria PJ, et al. Systemic chemotherapies retain antitumor activity in desmoid tumors independent of specific mutations in CTNNB1 or APC: a multi-institutional retrospective study. Clin Cancer Res. 2022;28(18):4092–104.CrossRefPubMedPubMedCentral
go back to reference Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localized resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet. 1997;350:1647–54.CrossRef
Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localized resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet. 1997;350:1647–54.CrossRef
go back to reference Reijers SJM, Davies E, Grunhagen DJ, Fiore M, Honore C, et al. Variation in response rates to isolated limb perfusion in different soft-tissue tumour subtypes: an international multi-centre study. Eur J Cancer. 2023;190: 112949.CrossRefPubMed
Reijers SJM, Davies E, Grunhagen DJ, Fiore M, Honore C, et al. Variation in response rates to isolated limb perfusion in different soft-tissue tumour subtypes: an international multi-centre study. Eur J Cancer. 2023;190: 112949.CrossRefPubMed
go back to reference Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387:1629–37.CrossRefPubMed
Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387:1629–37.CrossRefPubMed
go back to reference Van Glabbeke M, Van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcomas: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens – a European organization for research and treatment of cancer soft tissue and bone sarcoma study. J Clin Oncol. 1999;17:150–7.CrossRefPubMed
Van Glabbeke M, Van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcomas: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens – a European organization for research and treatment of cancer soft tissue and bone sarcoma study. J Clin Oncol. 1999;17:150–7.CrossRefPubMed
go back to reference Verschoor AJ, Bovée JVMG, Overbeek LIH; PALGA group, Hogendoorn PCW, Gelderblom H. The incidence, mutational status, risk classification and referral pattern of gastro-intestinal stromal tumours in the Netherlands: a nationwide pathology registry (PALGA) study. Virchows Arch. 2018;472:221–9.
Verschoor AJ, Bovée JVMG, Overbeek LIH; PALGA group, Hogendoorn PCW, Gelderblom H. The incidence, mutational status, risk classification and referral pattern of gastro-intestinal stromal tumours in the Netherlands: a nationwide pathology registry (PALGA) study. Virchows Arch. 2018;472:221–9.
go back to reference Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127–34.CrossRefPubMed
Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127–34.CrossRefPubMed
go back to reference WHO classification of Tumours Editorial Board. WHO classification of tumours of soft tissue and bone. 5th ed., 2020 https://whobluebooks.iarc.fr/publications/index.php.
WHO classification of Tumours Editorial Board. WHO classification of tumours of soft tissue and bone. 5th ed., 2020 https://whobluebooks.iarc.fr/publications/index.php.
Metagegevens
- Titel
- Maligne tumoren van de weke delen
- Auteurs
-
W. T. A. van der Graaf
J. V. M. G. Bovée
R. L. M. Haas
D. J. Grünhagen
- Copyright
- 2025
- Uitgeverij
- BSL Media & Learning
- Boek
-
Leerboek oncologie – online voorpublicatie
Print ISBN: 978-90-368-3113-0
Elektronisch ISBN: 978-90-368-3114-7
Copyright: 2025
- DOI
- https://doi.org/10.1007/978-90-368-3114-7_21